Aduro drug to be tested with Keytruda in second indication

17 May 2017

Aduro Biotech’s (Nasdaq: ADRO) LADD (live, attenuated double-deleted) based immunotherapy is to be tested in a second Phase II trial with Keytruda (pembrolizumab), the big-hitting immuno-oncology drug from US pharma giant Merck & Co (NYSE: MRK).

The combination of Aduro’s CRS-207 and Merck's anti-PD-1 therapy will be trialled in patients with malignant pleural mesothelioma (MPM) whose disease progressed following prior treatment. Earlier this year, the companies announced that the same two drugs would enter a Phase II trial in gastric cancer.

Natalie Sacks, chief medical officer at Aduro, said: “Data from our ongoing Phase I clinical trial of CRS-207 with standard chemotherapy as frontline treatment for MPM have been very encouraging, including disease control in 94% of patients treated with the CRS-207/chemotherapy combination.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK